Biogen (BIIB) Cash from Investing Activities (2009 - 2026)

Biogen has reported Cash from Investing Activities for 18 years, with the latest figure at -$3.8 billion in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 6635.44% year-over-year to -$3.8 billion in Q2 2026; TTM through Jun 2026 was -$5.3 billion, a 307.63% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 71.56% from the prior year.
• Cash from Investing Activities was -$3.8 billion for Q2 2026 at Biogen, down from -$209.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2022, with the low at -$3.8 billion in Q2 2026.
• Average Cash from Investing Activities over 5 years is -$485.7 million, with a median of -$175.3 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities surged 815.84% in 2022, then slumped 6635.44% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$141.1 million in 2022, then sank by 362.3% to -$652.3 million in 2023, then surged by 97.15% to -$18.6 million in 2024, then plunged by 6522.04% to -$1.2 billion in 2025, then tumbled by 211.7% to -$3.8 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$3.8 billion (Q2 2026), -$209.5 million (Q1 2026), and -$1.2 billion (Q4 2025), per Business Quant data.